LIU Xianbing,LI Fang,CHEN Xiaoping, et al. Effect of long-term and low-doses roxithromycin on airway local immune in patients with moderately severe COPD[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2015, 45(10 ): 734-.
Abstract：Objective: To discusses effect on the airway local immune of long-term and low-dose roxithromycin and clinical significance of patients with moderately severe chronic obstructive pulmonary diseases (COPD). Methods: Sixty patients with moderately severe COPD were randomly divided into two groups (n=30): the roxithromycin and basic group. Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation combined with totropium Bromide Powder for Inhalation were used as the foundation treatment. The roxithromycin group combined with roxithromycin 150 mg, 1/d, oral. Both groups were followed up for a year, once every three months. Sixty cases of healthy check-up were as healthy controls. The CAT score, FEV, seurm lgG, lgA, lgM and induced sputum CD3+, CD4+, CD4+/CD8+, etc were tested and compared. Results: Compared with healthy group, the lgA, IgG of COPD group was decreased, serum induced sputum CD3+, CD4+, CD4+/CD8+ value was decreased, CD8+ increased (P<0.05). There was no significant difference between two groups of COPD (P>0.05). After three months, the lgA, IgG and induced sputum CD3+, CD4+, CD4+/CD8+ of roxithromycin group was increased, CD8+ decreased (P<0.05). CAT score decreased and FEV1 improved (P<0.05). Peak reached after six months of treatment (P<0.05). There was no significant difference both nine months and twelve months of treatment (P<0.05). In roxithromycin group, induced sputum CD4+/CD8+ and IgG, IgA, FEV1 had positive correlation (r=0.567, 0.587, 0.556, P<0.05), and the CAT score had negative correlation (r=-0.507, P<0.05). Conclusion: Long-term and low doses of roxithromycin use can improve the body airway partial immunity and quality of life of COPD patients. Long-term use of roxithromycin benefit is bigger.
